174 related articles for article (PubMed ID: 23122450)
1. Urosdeoxycholic acid in primary sclerosing cholangitis: a meta-analysis and systematic review.
Othman MO; Dunkelberg J; Roy PK
Arab J Gastroenterol; 2012 Sep; 13(3):103-10. PubMed ID: 23122450
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis.
Triantos CK; Koukias NM; Nikolopoulou VN; Burroughs AK
Aliment Pharmacol Ther; 2011 Oct; 34(8):901-10. PubMed ID: 21883323
[TBL] [Abstract][Full Text] [Related]
3. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.
Mitchell SA; Bansi DS; Hunt N; Von Bergmann K; Fleming KA; Chapman RW
Gastroenterology; 2001 Oct; 121(4):900-7. PubMed ID: 11606503
[TBL] [Abstract][Full Text] [Related]
4. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
Lindor KD; Kowdley KV; Luketic VA; Harrison ME; McCashland T; Befeler AS; Harnois D; Jorgensen R; Petz J; Keach J; Mooney J; Sargeant C; Braaten J; Bernard T; King D; Miceli E; Schmoll J; Hoskin T; Thapa P; Enders F
Hepatology; 2009 Sep; 50(3):808-14. PubMed ID: 19585548
[TBL] [Abstract][Full Text] [Related]
5. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
Smith T; Befeler AS
Curr Gastroenterol Rep; 2007 Mar; 9(1):54-9. PubMed ID: 17335678
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
Boberg KM; Schrumpf E
Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
[TBL] [Abstract][Full Text] [Related]
7. Bile acids for primary sclerosing cholangitis.
Poropat G; Giljaca V; Stimac D; Gluud C
Cochrane Database Syst Rev; 2011 Jan; 2011(1):CD003626. PubMed ID: 21249655
[TBL] [Abstract][Full Text] [Related]
8. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis.
Lindström L; Hultcrantz R; Boberg KM; Friis-Liby I; Bergquist A
Clin Gastroenterol Hepatol; 2013 Jul; 11(7):841-6. PubMed ID: 23353641
[TBL] [Abstract][Full Text] [Related]
9. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial.
Färkkilä M; Karvonen AL; Nurmi H; Nuutinen H; Taavitsainen M; Pikkarainen P; Kärkkäinen P
Hepatology; 2004 Dec; 40(6):1379-86. PubMed ID: 15565569
[TBL] [Abstract][Full Text] [Related]
10. Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis?
van Milligen de Wit AW; Kuiper H; Camoglio L; van Bracht J; Jones EA; Tytgat GN; van Deventer SJ
Eur J Gastroenterol Hepatol; 1999 Feb; 11(2):129-36. PubMed ID: 10102223
[TBL] [Abstract][Full Text] [Related]
11. Ursodeoxycholic acid for primary biliary cirrhosis.
Gong Y; Huang ZB; Christensen E; Gluud C
Cochrane Database Syst Rev; 2008 Jul; (3):CD000551. PubMed ID: 18677775
[TBL] [Abstract][Full Text] [Related]
12. Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis.
Singh S; Khanna S; Pardi DS; Loftus EV; Talwalkar JA
Inflamm Bowel Dis; 2013 Jul; 19(8):1631-8. PubMed ID: 23665966
[TBL] [Abstract][Full Text] [Related]
13. Bile acids for primary sclerosing cholangitis.
Chen W; Gluud C
Cochrane Database Syst Rev; 2003; (2):CD003626. PubMed ID: 12804480
[TBL] [Abstract][Full Text] [Related]
14. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience.
Lemoinne S; Pares A; Reig A; Ben Belkacem K; Kemgang Fankem AD; Gaouar F; Poupon R; Housset C; Corpechot C; Chazouillères O
Clin Res Hepatol Gastroenterol; 2018 Dec; 42(6):521-528. PubMed ID: 30100231
[TBL] [Abstract][Full Text] [Related]
15. Primary sclerosing cholangitis.
Stiehl A; Benz C; Sauer P
Can J Gastroenterol; 2000 Apr; 14(4):311-5. PubMed ID: 10799084
[TBL] [Abstract][Full Text] [Related]
16. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
Holtmeier J; Leuschner U
Digestion; 2001; 64(3):137-50. PubMed ID: 11786661
[TBL] [Abstract][Full Text] [Related]
17. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis.
Charatcharoenwitthaya P; Angulo P; Enders FB; Lindor KD
Hepatology; 2008 Jan; 47(1):133-42. PubMed ID: 17992695
[TBL] [Abstract][Full Text] [Related]
18. Ursodeoxycholic acid is associated with improved long-term outcome in patients with primary sclerosing cholangitis.
Arizumi T; Tazuma S; Isayama H; Nakazawa T; Tsuyuguchi T; Takikawa H; Tanaka A;
J Gastroenterol; 2022 Nov; 57(11):902-912. PubMed ID: 36068441
[TBL] [Abstract][Full Text] [Related]
19. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia.
Lindström L; Boberg KM; Wikman O; Friis-Liby I; Hultcrantz R; Prytz H; Sandberg-Gertzén H; Sangfelt P; Rydning A; Folvik G; Gangsøy-Kristiansen M; Danielsson A; Bergquist A
Aliment Pharmacol Ther; 2012 Feb; 35(4):451-7. PubMed ID: 22221173
[TBL] [Abstract][Full Text] [Related]
20. Primary sclerosing cholangitis and bile acids.
Chazouillères O
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S21-5. PubMed ID: 23141889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
